Sol-Gel Technologies Ltd. (SLGL): Price and Financial Metrics
GET POWR RATINGS... FREE!
SLGL Stock Summary
- The ratio of debt to operating expenses for SOL-GEL TECHNOLOGIES LTD is higher than it is for about just 9.56% of US stocks.
- With a year-over-year growth in debt of -33.42%, SOL-GEL TECHNOLOGIES LTD's debt growth rate surpasses merely 9.23% of about US stocks.
- Revenue growth over the past 12 months for SOL-GEL TECHNOLOGIES LTD comes in at 471.6%, a number that bests 97.85% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to SOL-GEL TECHNOLOGIES LTD, a group of peers worth examining would be HYLN, ERYP, IPSC, DRRX, and DBVT.
- Visit SLGL's SEC page to see the company's official filings. To visit the company's web site, go to www.sol-gel.com.
SLGL Valuation Summary
- SLGL's EV/EBIT ratio is 9.5; this is 25% higher than that of the median Healthcare stock.
- Over the past 58 months, SLGL's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for SLGL.
SLGL Stock Price Chart Interactive Chart >
SLGL Price/Volume Stats
|Current price||$4.55||52-week high||$8.51|
|Prev. close||$4.67||52-week low||$3.94|
|Day high||$4.90||Avg. volume||11,111|
|50-day MA||$4.90||Dividend yield||N/A|
|200-day MA||$5.86||Market Cap||105.24M|
Sol-Gel Technologies Ltd. (SLGL) Company Bio
Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company’s lead product candidates include VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea; and TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris. It is also involved in the development of generic dermatological candidates; and formulation and pre-clinical development of early stage product candidates for acne and rosacea, and other dermatological indications. The company was founded in 1997 and is based in Ness Ziona, Israel
Most Popular Stories View All
SLGL Latest News Stream
|Loading, please wait...|
SLGL Latest Social Stream
View Full SLGL Social Stream
Latest SLGL News From Around the Web
Below are the latest news stories about SOL-GEL TECHNOLOGIES LTD that investors may wish to consider to help them evaluate SLGL as an investment opportunity.
Analysts Offer Insights on Healthcare Companies: Sol-Gel Technologies (SLGL), Zentalis Pharmaceuticals (ZNTL) and Oncology Institute, Inc. (TOI)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sol-Gel Technologies (SLGL – Research Report), Zentalis Pharmaceuticals (ZNTL – Research Report) and Oncology Institute, Inc. (TOI – Research Report) with bullish sentiments. Sol-Gel Technologies (SLGL) Raymond James analyst Elliot Wilbur maintained a Buy rating on Sol-Gel Technologies today and set a price target of $13.00. The company's shares closed last Friday at $4.74, close to its 52-week low of $3.94. According to TipRanks.
Growth trends for TWYNEO and EPSOLAY continue to improve, demonstrating robust uptake by prescribersSol-Gel’s cash runway expected to extend through the end of the first quarter of 2024 NESS ZIONA, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today financial results for the third qua
Sol-Gel Technologies (NASDAQ:SLGL) investors are sitting on a loss of 45% if they invested a year ago
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. But if...
NESS ZIONA, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today the appointment of Michael Glezin to the position of Vice President, Business Development. In this position, Mr. Glezin will be responsible for identifying new in-licensing business opportunities as well as potential comm
Are Strong Financial Prospects The Force That Is Driving The Momentum In Sol-Gel Technologies Ltd.'s NASDAQ:SLGL) Stock?
Sol-Gel Technologies (NASDAQ:SLGL) has had a great run on the share market with its stock up by a significant 20% over...
SLGL Price Returns
Continue Researching SLGLWant to see what other sources are saying about Sol-Gel Technologies Ltd's financials and stock price? Try the links below:
Sol-Gel Technologies Ltd (SLGL) Stock Price | Nasdaq
Sol-Gel Technologies Ltd (SLGL) Stock Quote, History and News - Yahoo Finance
Sol-Gel Technologies Ltd (SLGL) Stock Price and Basic Information | MarketWatch